Benitec Biopharma Limited (BNTC) closed the last trading session at $15.49, gaining 14.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $25.71 indicates a 66% upside potential.The average comprises seven short-term price targets ranging from a low of $17 to a high of $35, with a standard deviation of $6.70. While the lowest estimate indicates an increase of 9.8% from the current ...

Knightscope, Inc. (KSCP) closed the last trading session at $6.06, gaining 25.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17 indicates an 180.5% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $11.36. While the lowest estimate of $9 indicates a 48.5% increase from the current price level, the most optimistic analyst e ...

Brainsway Ltd. Sponsored ADR (BWAY) closed the last trading session at $10.46, gaining 20.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $15.05 indicates a 43.9% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $0.74. While the lowest estimate of $14.20 indicates a 35.8% increase from the current price level, the most optim ...

Fresenius (FMS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings pictu ...

Core Viewpoint - FTAI Aviation (FTAI) has shown a significant price increase of 14.2% over the past four weeks, with analysts projecting a mean price target of $171, indicating a potential upside of 38.6% from the current price of $123.35 [1] Price Targets and Analyst Consensus - The average price target for FTAI includes 12 short-term estimates ranging from a low of $123 to a high of $300, with a standard deviation of $46.90, suggesting variability in analyst predictions [2] - The lowest estimate indicates a slight decline of 0.3%, while the highest estimate suggests a substantial upside of 143.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding FTAI's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 1.7% over the past month, with one estimate rising and no negative revisions [12] - FTAI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13]

Shares of Agenus (AGEN) have gained 68.4% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.33 indicates a potential upside of 26.6%.The mean estimate comprises three short-term price targets with a standard deviation of $2.08. While the lowest estimate of $4 indicates a 20% decline from the current price level, ...

Core Viewpoint - Rambus (RMBS) has shown a significant price increase of 12.2% over the past four weeks, with a mean price target of $72.25 indicating a potential upside of 28.3% from the current price of $56.30 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $9.97, where the lowest estimate is $55 (indicating a 2.3% decline) and the highest estimate is $90 (indicating a 59.9% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about RMBS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 2% increase in the Zacks Consensus Estimate over the past month [11][12] - RMBS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead, as empirical research indicates that they rarely predict actual stock price movements accurately [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Zymeworks Inc. (ZYME) shows potential for significant upside, with a mean price target of $21.35 indicating a 76.7% increase from its current price of $12.08 [1] Price Targets and Estimates - The mean estimate consists of 10 short-term price targets with a standard deviation of $7.45, indicating variability among analysts [2] - The lowest estimate is $12, suggesting a slight decline of 0.7%, while the highest estimate predicts a surge of 148.3% to $30 [2] - Analysts' price targets are often questioned for their reliability, as they may mislead investors rather than provide accurate guidance [3][7] Earnings Estimates and Analyst Agreement - Analysts are optimistic about ZYME's earnings, with a consensus indicating better-than-previously estimated earnings [4] - The Zacks Consensus Estimate for the current year has risen by 6.2% over the past month, with four estimates increasing and no negative revisions [12] - A strong correlation exists between earnings estimate revisions and near-term stock price movements, suggesting potential upside for ZYME [11] Zacks Rank and Investment Potential - ZYME holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [13]

Energy Transfer LP (ET) closed the last trading session at $17.90, gaining 13.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.93 indicates a 28.1% upside potential.The average comprises 14 short-term price targets ranging from a low of $19 to a high of $26, with a standard deviation of $1.94. While the lowest estimate indicates an increase of 6.2% from the current price leve ...

Shares of Knot Offshore (KNOP) have gained 0.3% over the past four weeks to close the last trading session at $6.39, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.17 indicates a potential upside of 106.1%.The average comprises three short-term price targets ranging from a low of $12 to a high of $15, with a standard deviation of $1.61. While the lowest estimate indicates a ...